New combo therapy aims to boost leukemia fight without harming transplant
NCT ID NCT05507827
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-phase trial tests whether giving specially engineered donor immune cells (CAR T cells) after a stem cell transplant is safe for adults with a high-risk type of B-cell leukemia. The goal is to strengthen the body's ability to fight remaining cancer cells without causing severe graft-versus-host disease. About 22 participants will receive the treatment and be monitored for side effects and leukemia relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford Cancer Center
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.